Is The Worst Over for Teladoc?
Teladoc Health (NYSE: TDOC) is finally getting some love from investors. After a catastrophic performance on the market in 2022, the telemedicine specialist has been rebounding since the beginning of the year. The company's latest quarterly report was also well-received by the market, which helped jolt its stock further.
But might these positive developments be temporary? Before jumping on the bandwagon, it's essential to look deeper into Teladoc's operations and determine whether the company has solid long-term prospects. Let's examine whether Teladoc has managed to move beyond the headwinds that haunted it last year.
Teladoc released its first-quarter earnings on April 26. The company showed progress in several areas. On the top line, the telemedicine expert saw its revenue increase 11% year over year to $629 million. Teladoc's top-line growth this time around seems unimpressive compared to the past two years.
Source Fool.com
